Numinus Wellness Inc. (TSX-V:NUMI, OTC:LKYSF) announced that it has received approval from Health Canada to study Ayahuasca and San Pedro at its licensed, state-of-the-art research facility, Numinus Bioscience, broadening its extensive list of permissible research and development (R&D) activities.
The company said the license expansion will further position it as a recognized global research centre for natural psychedelic medicines, and supplements the current work Numinus is already undertaking on Psilocybe species and inherent synergistic compounds.
“Many naturally occurring psychedelic compounds have already been in traditional use for millennia,” Numinus Wellness CEO Payton Nyquvest said in a statement.
READ: Numinus Wellness research facility licensed by Health Canada to supply psilocybin mushrooms
“These amendments honour and build on those practices while allowing us to do novel clinical research and deepen the body of scientific data for scaled development and greater public access to much-needed therapies,” Nyquvest added.
Numinus noted it is now permitted to work with the San Pedro cactus, the beta-carbolines harmaline and harmalol, and the following botanical materials: Banisteriopsis caapi, Psychotria viridis, Diplopterys cabrerana, Mimosa tenuiflora.
It added that the botanical materials are notable for their role as admixtures to Ayahuasca, a psychoactive brew made from multiple plant materials and consumed in Amazonian Indigenous traditional practices for ceremonial, medicinal and spiritual purposes.
The company also said research will be done to develop standardized analytical methods for the starting materials, finished Ayahuasca brews, and San Pedro, which contains the psychedelic compound mescaline.
Approved activities for its license expansion include possession, analytical testing, production, assembly, sale, export and delivery, according to the company.
Numinus Wellness helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model – including psychedelic production, research and clinic care – is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use.
Contact Sean at sean@proactiveinvestors.com